aTyr Pharma (NASDAQ:LIFE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “

Separately, ValuEngine lowered aTyr Pharma from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $4.81.

aTyr Pharma (NASDAQ LIFE) opened at $4.00 on Wednesday. The firm has a market capitalization of $116.06, a price-to-earnings ratio of -1.97 and a beta of 3.83. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.49 and a current ratio of 9.49. aTyr Pharma has a 12 month low of $2.30 and a 12 month high of $6.50.

aTyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.43) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.07. equities analysts forecast that aTyr Pharma will post -1.93 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in LIFE. Artal Group S.A. acquired a new position in shares of aTyr Pharma in the 3rd quarter valued at $1,263,000. Victory Capital Management Inc. acquired a new position in shares of aTyr Pharma in the 3rd quarter valued at $455,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of aTyr Pharma by 44.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock valued at $423,000 after purchasing an additional 25,676 shares during the last quarter. 58.28% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/17/atyr-pharma-life-downgraded-to-hold-at-zacks-investment-research.html.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get a free copy of the Zacks research report on aTyr Pharma (LIFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.